Key facts
- Lucid Scientific’s last known valuation is $26.9M (Sep 2023).
- It has raised $13.0M across 2 recorded rounds; the latest was Early Stage VC ($8.9M) in Aug 2023.
- Notable investors include IAG Capital Partners, Advanced Technology Development Center, Dynamk Capital, GRA Venture Fund.
- Lucid Scientific has filed 2 Form Ds with the SEC since 2020, most recently Sep 2023 ($8.9M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Lucid Scientific
Funding rounds
2 roundsAbout Lucid Scientific
Developer of metabolic cell analysis instruments designed for continuous bioenergetic monitoring. The company's platform measures real-time oxygen consumption and mitochondrial function across diverse plate formats and culture types inside standard incubators, enabling life science researchers to assess cell metabolism over extended experiments.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2012
- Employees
- 17
- Website
- lucidsci.com/
- Ownership
- Privately Held (backing)
Lucid Scientific doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lucid Scientific shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lucid Scientific in its N-PORT filings yet. We sweep new filings monthly.